Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms

2022/11/01 by Murray Epstein, Csaba P. Kovesdy, Catherine M. Clase +2 · 2 citations

paper · doi:10.1053/j.ajkd.2022.04.016

Cited by

• Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis
• The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease